cDC1 are thought to perform cross-presentation for CD8+ T cell priming.3,46 Our study demonstrated that targeting BCL9/BCL9L facilitates antigen presentation by promoting cDC1 activation and tumor infiltration. The gene discussed is CD8A; the disease is neoplasm.